Unraveling the Potential of C18orf63: A novel protein Target for Drug Development

Target Name: C18orf63

NCBI ID: G644041

C18orf63

Other Name(s): Uncharacterized protein C18orf63 | CR063_HUMAN | chromosome 18 open reading frame 63 | DKFZP781G0119 | Chromosome 18 open reading frame 63

Unraveling the Potential of C18orf63: A novel protein Target for Drug Development

C18orf63 is a non-coding RNA molecule located in chromosome 18. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The discovery of C18orf63 as a potential drug target has generated significant interest in the research community and has the potential to revolutionize our understanding of these diseases. In this article, we will provide an overview of C18orf63, its potential drug targets, and its implications for future drug development.

Overview of C18orf63

C18orf63 is a small non-coding RNA molecule that is expressed in various tissues and cell types. It is characterized by a unique 18-nt stem-loop structure, which is composed of a combination of single- and double-stranded regions. C18orf63 is primarily expressed in the brain and has been shown to play a role in various neural functions, including neuronal communication and synaptic plasticity.

Drug Target Potential

C18orf63 has been identified as a potential drug target due to its unique structure and various biological processes that it is involved in. One of the key reasons for its potential as a drug target is its unique expression pattern, which has been shown to be different between various tissues and cell types. For example, C18orf63 is highly expressed in the brain, while its expression is much lower in other tissues, such as muscle and heart.

Another potential drug target for C18orf63 is its involvement in various signaling pathways, including the TGF-灏? pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer and neurodegenerative disorders.

C18orf63 has also been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and survival. Its expression has been shown to be regulated by various factors, including growth factors, chemokines, and pro-inflammatory cytokines.

Biomarker Potential

C18orf63 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its expression has been shown to be altered in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, C18orf63 has been shown to be downregulated in various types of cancer, while its expression is increased in neurodegenerative disorders.

C18orf63 has also been shown to be involved in the regulation of various signaling pathways, including the TGF-灏? pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer and neurodegenerative disorders.

Conclusion

In conclusion, C18orf63 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and various biological processes that it is involved in make it an attractive target for drug development. Further research is needed to fully understand the potential of C18orf63 as a drug target and biomarker, and to develop safe and effective treatments for various diseases.

Protein Name: Chromosome 18 Open Reading Frame 63

The "C18orf63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C18orf63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets